Literature DB >> 11796430

Nasal polyps in cystic fibrosis: clinical endoscopic study with nasal lavage fluid analysis.

Gert Henriksson1, Karl Magnus Westrin, Ferenc Karpati, Ann-Charlotte Wikström, Pontus Stierna, Lena Hjelte.   

Abstract

STUDY
OBJECTIVES: Nasal polyps frequently appear in patients with cystic fibrosis (CF). The aims of this study were to focus on what problems (symptoms, endoscopic findings, and laboratory correlates) nasal polyps cause the CF patient, and how these correlate to the total health situation of this patient group. PATIENTS AND STUDY
DESIGN: The clinical histories, endoscopic investigations of the nasal cavity, and analyses of nasal lavage fluid of 44 patients with CF complicated with nasal polyposis have been compared with those of 67 CF control subjects. The patients were examined at annual control examinations (with pulmonary tests, working capacity, liver tests, and bacterial and blood tests) from 1995 to 1996 at Stockholm Cystic Fibrosis Center, Huddinge University Hospital. All patients were > 2 years of age. The endoscopic findings were related to the actual pulmonary function, inflammatory blood parameters, colonizing pathogens, antibodies (Staphylococcus aureus and Pseudomonas aeruginosa), and genotype.
RESULTS: The patients with nasal polyps differed with respect to chronic colonization of P aeruginosa in sputum samples and had a higher occurrence of serum antibodies against the same species. The two groups did not differ in pulmonary functions, inflammatory parameters, or genotype. The polyps found were mainly small (within the meatus media) and gave no significant increase in ongoing clinical symptoms such as rhinorrhea, nasal obstruction, or hyposmia. Neither was any significantly marked finding concerning the nose (mucosal swellings, secretion, etc.) made in the polyp patients. The patients with CF scored slightly lower in a smell identification test in comparison with the healthy control group. The nasal lavage fluid was analyzed (in 93 of the 111 patients) for the occurrence of P aeruginosa (by polymerase-chain reaction [PCR]), interleukin [IL]-5, IL-8, and lysozyme. The lysozyme and IL-8 content was equal in the two CF groups but increased in comparison with the healthy control group. P aeruginosa was not detected with PCR in any nasal lavage fluid. No measurable levels of IL-5 in the nasal lavage were found.
CONCLUSIONS: There was a higher frequency of chronic colonization of P aeruginosa in the lower respiratory tract in patients with nasal polyps. Otherwise, nonsevere nasal polyposis was not an indicator of lower respiratory tract morbidity in CF patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796430     DOI: 10.1378/chest.121.1.40

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

1.  Analysis of most common CFTR mutations in patients affected by nasal polyps.

Authors:  Marzena Kostuch; Janusz Klatka; Andrzej Semczuk; Jacek Wojcierowski; Lucas Kulczycki; Jan Oleszczuk
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-06-17       Impact factor: 2.503

2.  Burkholderia cepacia complex nasal isolation in immunocompetent patients with sinonasal polyposis not associated with cystic fibrosis.

Authors:  G Marioni; R Rinaldi; C Staffieri; G Ottaviano; R Marchese-Ragona; L Giacomelli; S M Ferraro; A Staffieri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

Review 3.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

4.  Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis.

Authors:  Frank W Virgin; Steven M Rowe; Mary B Wade; Amit Gaggar; Kevin J Leon; K Randall Young; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2012 Jan-Feb       Impact factor: 2.467

5.  Prevalence of rhinosinusitis among atypical cystic fibrosis patients.

Authors:  Tal Marshak; Y Rivlin; L Bentur; O Ronen; N Uri
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-09-15       Impact factor: 2.503

6.  Sinonasal characteristics and quality of life by SNOT-22 in adult patients with cystic fibrosis.

Authors:  Suzie Hyeona Kang; Camila Degen Meotti; Karine Bombardelli; Otávio Bejzman Piltcher; Paulo de Tarso Roth Dalcin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-18       Impact factor: 2.503

Review 7.  Topical nasal steroids for treating nasal polyposis in people with cystic fibrosis.

Authors:  Helen Beer; Kevin W Southern; Andrew C Swift
Journal:  Cochrane Database Syst Rev       Date:  2015-06-22

8.  Antifungal immune reactivity in nasal polyposis.

Authors:  Lucia Pitzurra; Silvia Bellocchio; Angela Nocentini; Pierluigi Bonifazi; Raffaele Scardazza; Luigi Gallucci; Fabrizio Stracci; Costantino Simoncelli; Francesco Bistoni; Luigina Romani
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

Review 9.  Pathogenesis and management of nasal polyposis in cystic fibrosis.

Authors:  Jochen G Mainz; Assen Koitschev
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 10.  Cystic fibrosis.

Authors:  Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush
Journal:  Nat Rev Dis Primers       Date:  2015-05-14       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.